Analysts Set Expectations for AcelRx Pharmaceuticals, Inc.’s FY2017 Earnings (ACRX)
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) – Equities researchers at Jefferies Group upped their FY2017 earnings per share (EPS) estimates for AcelRx Pharmaceuticals in a note issued to investors on Tuesday. Jefferies Group analyst M. Andrews now forecasts that the specialty pharmaceutical company will post earnings of ($1.00) per share for the year, up from their previous estimate of ($1.02). Jefferies Group has a “Hold” rating on the stock. Jefferies Group also issued estimates for AcelRx Pharmaceuticals’ Q4 2017 earnings at ($0.21) EPS, FY2018 earnings at ($1.13) EPS, FY2019 earnings at ($0.85) EPS, FY2020 earnings at ($1.14) EPS and FY2021 earnings at ($0.93) EPS.
Several other analysts also recently weighed in on ACRX. ValuEngine upgraded shares of AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Piper Jaffray Companies set a $3.00 target price on shares of AcelRx Pharmaceuticals and gave the company a “hold” rating in a report on Tuesday, July 25th. Cowen and Company reiterated a “hold” rating on shares of AcelRx Pharmaceuticals in a report on Tuesday, August 1st. Roth Capital set a $13.00 target price on shares of AcelRx Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 2nd. Finally, Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $6.83.
Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) opened at $2.05 on Thursday. AcelRx Pharmaceuticals has a 1-year low of $1.55 and a 1-year high of $5.75. The company has a debt-to-equity ratio of -0.43, a current ratio of 4.78 and a quick ratio of 4.71.
Several large investors have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its stake in shares of AcelRx Pharmaceuticals by 6.6% in the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock worth $355,000 after acquiring an additional 6,942 shares in the last quarter. Perennial Advisors LLC acquired a new position in shares of AcelRx Pharmaceuticals in the third quarter worth $138,000. WealthTrust Axiom LLC grew its stake in shares of AcelRx Pharmaceuticals by 50.0% in the second quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock worth $451,000 after acquiring an additional 70,000 shares in the last quarter. Geller Family Office Services LLC acquired a new position in shares of AcelRx Pharmaceuticals in the third quarter worth $460,000. Finally, Virtu KCG Holdings LLC grew its stake in shares of AcelRx Pharmaceuticals by 600.9% in the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after acquiring an additional 101,742 shares in the last quarter. Institutional investors and hedge funds own 23.09% of the company’s stock.
In other AcelRx Pharmaceuticals news, Director Mark G. Edwards purchased 30,000 shares of the company’s stock in a transaction on Tuesday, November 14th. The stock was acquired at an average price of $1.90 per share, for a total transaction of $57,000.00. Following the completion of the purchase, the director now directly owns 150,000 shares in the company, valued at approximately $285,000. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, insider Pamela P. Palmer purchased 10,000 shares of the company’s stock in a transaction on Tuesday, August 22nd. The stock was acquired at an average price of $2.95 per share, with a total value of $29,500.00. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 72,000 shares of company stock valued at $178,980. Insiders own 28.10% of the company’s stock.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.